What Is Victoza?

Victoza (liraglutide 1.8 mg) is a once-daily injectable GLP-1 receptor agonist approved by the FDA in January 2010 for type 2 diabetes management. It was one of the first GLP-1 medications to demonstrate cardiovascular outcome benefits, reducing major adverse cardiovascular events by 13% in the LEADER trial (2016). Victoza contains the same liraglutide molecule as Saxenda but is dosed and labeled specifically for diabetes.

Formulation: Once-daily subcutaneous injection (6 mg/mL multi-dose pen: 0.6, 1.2, 1.8 mg doses)

Mechanism: GLP-1 receptor agonist

Manufacturer: Novo Nordisk official patient site ↗

FDA Approved: 2010 — Key Trial: LEADER ↗ (ClinicalTrials.gov)

Who Is Victoza For?

FDA-Approved Indication: Type 2 diabetes management; cardiovascular risk reduction in T2D with established CVD

Adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Also indicated to reduce the risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease. Note: Victoza is not approved for weight management — Saxenda (same molecule at higher dose) has that indication.

Eligibility criteria: BMI criterion not required; indicated for T2D management

Dosing & Titration Schedule

The standard titration protocol for Victoza (Liraglutide) allows your body to adjust gradually to the medication, minimizing GI side effects. Each dose is typically maintained for 4 weeks before escalation, though your prescriber may modify this based on tolerability.

Dose	Approx. Weeks	Frequency	Phase
0.6 mg	Wk 1–4	Daily	▶ Starting dose
1.2 mg	Wk 5–8	Daily	→ Escalation
1.8 mg	Wk 9–12	Daily	→ Escalation
2.4 mg	Wk 13–16	Daily	→ Escalation
3.0 mg	Wk 17–20	Daily	★ Maintenance

Data source: FDA Prescribing Information for Victoza. Individual titration may vary based on tolerability and clinical response.

Weight Loss & Glycemic Outcomes

Clinical trial evidence (LEADER): ~3–4% body weight reduction (LEADER trial, T2D population)

Cardiovascular benefit: Victoza has demonstrated cardiovascular outcome benefits in clinical trials. Discuss cardiovascular risk reduction with your prescriber.

These figures are based on clinical trial populations meeting specific inclusion criteria. Real-world results may differ due to adherence, diet, activity level, and individual biology. Calculate your projected weight loss →

Side Effect Profile

The most commonly reported side effects of Victoza are GI-related, typically most pronounced during dose escalation. They generally improve within 2–4 weeks at a stable dose.

•Nausea
•Diarrhea
•Constipation
•Vomiting
•Headache
•Injection Site Reaction
•Fatigue

For detailed guidance on managing specific side effects, see the Liraglutide side effects hub →

Cost Overview

Scenario	Estimated Monthly Cost
Cash pay (no insurance)	$700–$900/month
Commercial insurance	$25–$50/month with commercial insurance and Novo Nordisk savings card
Manufacturer savings program	Novo Nordisk Victoza Savings Card — eligible commercially insured patients may significantly reduce out-of-pocket costs

Estimated based on Q1 2026 data. Prices vary by pharmacy, region, and insurance plan. Always verify current pricing with your pharmacy or plan.

Visit Novo Nordisk’s savings program ↗ | Estimate your monthly cost →

Safety & Contraindications

Victoza carries a Boxed Warning regarding the risk of thyroid C-cell tumors (based on animal studies). The clinical relevance in humans is unknown, but the following contraindications apply:

Personal or family history of medullary thyroid carcinoma
MEN type 2 syndrome
Hypersensitivity to liraglutide

Pregnancy: Victoza is not recommended during pregnancy. Discontinue at least 2 months before a planned pregnancy when possible. Discuss contraception and family planning with your prescriber.

Drug interactions: Delayed gastric emptying; hypoglycemia risk with insulin/sulfonylureas.

How Does Victoza Compare to Other Options?

See all brand comparisons →

Frequently Asked Questions

How is Victoza different from Saxenda?

Both contain liraglutide but at different approved doses and indications. Victoza goes up to 1.8 mg daily for type 2 diabetes. Saxenda goes up to 3.0 mg daily for weight management. If diabetes control and modest weight loss are both goals, Victoza is the appropriate starting point.

Does Victoza help with weight loss?

Weight loss is a secondary benefit of Victoza, not its primary purpose. In the LEADER trial (T2D patients), Victoza users lost approximately 2–4% body weight. For weight loss as a primary goal, Saxenda (3.0 mg liraglutide) or newer agents like Wegovy or Zepbound are more appropriate.

What is the LEADER trial?

LEADER was a landmark cardiovascular outcomes trial (N=9,340, median 3.8 years) showing Victoza reduced major adverse cardiovascular events (MACE) by 13% vs placebo in T2D patients with high CV risk. This led to the cardiovascular risk reduction indication (2017).

What does the Victoza titration schedule look like?

Start at 0.6 mg daily (week 1, a tolerability dose, not a therapeutic dose) → 1.2 mg (week 2) → 1.8 mg (week 3 onward, if needed for additional glycemic control). Most patients achieve target HbA1c at 1.2 mg.

Is Victoza still widely used given newer options?

Victoza's market share has declined with the availability of semaglutide and tirzepatide, which offer superior efficacy. However, Victoza remains prescribed for: established patients doing well, formulary/cost reasons, and its long safety record in T2D management.

Can I switch from Victoza to Ozempic?

Yes — switching from Victoza (liraglutide) to Ozempic (semaglutide) is a common clinical transition. Both are GLP-1 agonists but semaglutide is more potent. Your prescriber will guide the appropriate starting dose and titration for Ozempic.

Is Victoza safe long-term?

Victoza has one of the longest real-world safety records of any GLP-1 medication, having been available since 2010. The LEADER trial followed patients for nearly 4 years without new safety signals beyond the established class risks.

Victoza: Complete Guide to Liraglutide (2026)